Insights into the Assessment of Measurable Residual Disease (MRD) in Patients With Multiple Myeloma

被引：0
|
作者：
Costa, Luciano J. [1 ,2 ,3 ]
机构：
[1] Univ Alabama Birmingham, Sch Med, Med, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Sch Med, ONeal Comprehens Canc Ctr Clin Trials Off, Birmingham, AL 35294 USA
[3] Univ Alabama Birmingham, Sch Med, Hematol Malignancies Working Grp, Hematol & Oncol, Birmingham, AL 35294 USA
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2020年 / 18卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：11 / 16
页数：6
相关论文
共 50 条
  • [31] Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria
    Narita, Kentaro
    Miura, Daisuke
    Tsushima, Takafumi
    Terao, Toshiki
    Kuzume, Ayumi
    Tabata, Rikako
    Takeuchi, Masami
    Matsue, Kosei
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [32] Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria
    Kentaro Narita
    Daisuke Miura
    Takafumi Tsushima
    Toshiki Terao
    Ayumi Kuzume
    Rikako Tabata
    Masami Takeuchi
    Kosei Matsue
    Scientific Reports, 11
  • [33] Reference materials for measurable residual disease (MRD) monitoring
    Konigshofer, Yves
    Butler, Matthew G.
    Dickens, Jessica
    Clement, Omoshile
    Anfora, Andrew
    Brudzewsky, Dan
    Anekella, Bharathi
    Garlick, Russell K.
    CANCER RESEARCH, 2020, 80 (16)
  • [34] Predictors and MRD-Driven Treatment Strategies of Unsustained Measurable Residual Disease Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
    Li, Xiaozhe
    Li, Juan
    BLOOD, 2024, 144 : 4710 - 4710
  • [35] MINIMAL RESIDUAL DISEASE DETECTION BY NEXT GENERATION FLOW-MRD IN MULTIPLE MYELOMA PATIENTS
    Sirianni, S.
    Gozzetti, A.
    Candi, V.
    Bocchia, M.
    Raspadori, D.
    HAEMATOLOGICA, 2016, 101 : S87 - S87
  • [36] Potential future direction of measurable residual disease evaluation in multiple myeloma
    Mohty, Mohamad
    Avet-Loiseau, Herve
    Malard, Florent
    Harousseau, Jean-Luc
    BLOOD, 2023, 142 (18) : 1509 - 1517
  • [37] Clinician attitudes and practices toward measurable residual disease in multiple myeloma
    Derman, Benjamin A.
    Jasielec, Jagoda K.
    Jakubowiak, Andrzej J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 190 (03) : 470 - 472
  • [38] Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma
    Guerrero, Camila
    Puig, Noemi
    Cedena, Maria-Teresa
    Calasanz, Maria-Jose
    Gutierrez, Norma C.
    Fernandez, Manuela
    Oriol, Albert
    Rios-Tamayo, Rafael
    Hernandez, Miguel-Teodoro
    Martinez-Martinez, Rafael
    Bargay, Joan
    de Arriba, Felipe
    Palomera, Luis
    Gonzalez-Rodriguez, Ana Pilar
    Perez, Marta -Sonia Gonzalez
    Orfao, Alberto
    Mateos, Maria -Victoria
    Martinez-Lopez, Joaquin
    Rosinol, Laura
    Blade, Joan
    Lahuerta, Juan -Jose
    San-Miguel, Jesus F.
    Paiva, Bruno
    BLOOD, 2024, 143 (07) : 597 - 603
  • [39] MAKING CLINICAL DECISIONS BASED ON MEASURABLE RESIDUAL DISEASE IMPROVES THE PROGNOSIS OF PATIENTS WITH MULTIPLE MYELOMA
    Joaquin, Martinez-Lopez
    Rafael, Alonso
    Wong Sandy, W.
    Rafael, Rios
    Nina, Shah
    Yanira, Ruiz-Heredia
    Jose Maria, Sanchez-Pina
    Ricardo, Sanchez
    Natasha, Bahri
    Irene, Zamanillo
    Maria, Poza
    Natalia, Buenhache
    Cristina, Encinas
    Luis, Juarez
    Santiago, Barrio
    Thomas, Martin
    Jeff, Wolf
    Maria Teresa, Cedena
    HAEMATOLOGICA, 2021, 106 (10) : 72 - 72
  • [40] Assessment of Measurable Residual Disease (MRD) in Adult Patients With Acute Lymphocytic Leukemia: Best Use and a Case Report
    Muffly, Lori
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (03)
12345